Home » Roche Claims 'Other Options' If Illumina Deal Fails

Roche Claims 'Other Options' If Illumina Deal Fails

Mar 06, 2012

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Chairman Franz Humer today said that the firm has "other options" if its bid to acquire Illumina fails.

Humer's statement was part of prepared remarks made for Roche's annual general meeting, held today in Basel, Switzerland, where the firm is based.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Retirement Moves

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura Dies

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

Shuffle at IBM Watson Health

Stat News reports that the head of IBM Watson Health is leaving her post.

This Week in PLOS

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

What's Popular?

In Clinical Sequencing

  1. ASHG: Dutch Nationwide NIPT Implementation Study Sees 42 Percent Uptake After First Year

  2. ASHG: RNA Sequencing Can Improve Diagnostic Yield of Exome, Genome Tests

  3. At ASHG, Researchers Discuss Newborn Sequencing's Potential, Challenges for Scaling

    Premium

  4. Singlera Genomics Presents Data on Cell-Free DNA Methylation Test for Early Cancer Detection

    Premium

  5. Lung Cancer Study Presented at ASHG Finds Pathogenic Germline Variants in 8.5 Percent of Patients

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.